Checkpoint blockade, agonistic antibodies to stimulatory molecules (e.g., OX40, CD137, CD27, and GITR) enhance the activation of T-cells and, as a result, boosted anti-tumor T cell responses. This evidence concerns the gene TNFRSF9 and neoplasm.